Vir Biotechnology, Inc. Deferred Income Tax Expense (Benefit)
Vir Biotechnology, Inc. (VIR) reported Deferred Income Tax Expense (Benefit) of $304.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-23.
Financial Statements › Cash Flow › Operating Activities
us-gaap:DeferredIncomeTaxExpenseBenefit · last filed 2026-02-23
- Vir Biotechnology, Inc. deferred income tax expense (benefit) for the quarter ending 2024-12-31 was -$2.64M.
- Vir Biotechnology, Inc. deferred income tax expense (benefit) for the quarter ending 2024-09-30 was $57.00K.
- Vir Biotechnology, Inc. deferred income tax expense (benefit) for the quarter ending 2023-12-31 was -$1.06M.
- Vir Biotechnology, Inc. deferred income tax expense (benefit) for the quarter ending 2023-09-30 was $0.00.
- Vir Biotechnology, Inc. deferred income tax expense (benefit) for fiscal 2025 was $304.00K.
- Vir Biotechnology, Inc. deferred income tax expense (benefit) for fiscal 2024 was -$2.95M.
- Vir Biotechnology, Inc. deferred income tax expense (benefit) for fiscal 2023 was -$1.06M.
- Vir Biotechnology, Inc. deferred income tax expense (benefit) for fiscal 2022 was -$15.19M, a 200.00% decline from fiscal 2021.
| Period end | Deferred Income Tax Expense (Benefit) 3 month | Deferred Income Tax Expense (Benefit) 6 month | Deferred Income Tax Expense (Benefit) 9 month | Deferred Income Tax Expense (Benefit) 12 month |
|---|---|---|---|---|
| 2025-12-31 | $304.00K 10-K · filed 2026-02-23 | |||
| 2024-12-31 | -$2.64M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | -$2.59M derived: sum of 2 quarters · filed 2026-02-23 | -$2.95M 10-K · filed 2026-02-23 | |
| 2024-09-30 | $57.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-04 | -$306.00K 10-Q · filed 2024-11-04 | ||
| 2024-06-30 | -$363.00K 10-Q · filed 2024-08-01 | |||
| 2023-12-31 | -$1.06M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | -$1.06M derived: sum of 2 quarters · filed 2026-02-23 | -$1.06M 10-K · filed 2026-02-23 | |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-04 | $0.00 10-Q · filed 2024-11-04 | ||
| 2023-06-30 | $0.00 10-Q · filed 2024-08-01 | |||
| 2022-12-31 | -$15.19M 10-K · filed 2025-02-27 | |||
| 2021-12-31 | $15.19M 10-K · filed 2024-02-26 | |||
| 2020-12-31 | -$52.00K 10-K · filed 2023-02-28 | |||
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | -$500.00K 10-K · filed 2021-02-25 | ||
| 2018-09-30 | -$500.00K 10-Q · filed 2019-11-19 | |||
| 2017-12-31 | -$10.92M 10-K · filed 2020-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |